source
- Young startups miss out on biotech venture funding rebound, MassBio saysA new report found that the sizes of seed rounds and Series A financings for Massachusetts biotech startups are going in opposite directions, as funding slows for young companies with the “riskiest…BioPharma Dive · 39m ago↗ source
- Preparing for Novartis showdown, Curium touts value of radiopharma supply resiliencyWhile Novartis’ Pluvicto is a blockbuster, Curium heads into talks with the FDA about the review of its rival drug candidate believing a competing product can make the supply chain more resilient.BioSpace · 39m ago↗ source
- FDA places second clinical hold on Regenxbio’s Hunter syndrome gene therapy after spinal masses detectedThe FDA issued another clinical hold on Regenxbio’s RGX-121 gene therapy for Hunter syndrome after investigators found spinal masses in five trial participants. The masses, observed on MRI scans,…